100,000 Shares in Bicara Therapeutics Inc. $BCAX Acquired by Cantor Fitzgerald L. P.

Cantor Fitzgerald L. P. bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 100,000 shares of the company’s stock, valued at approximately $1,579,000.

A number of other institutional investors also recently added to or reduced their stakes in BCAX. Legal & General Group Plc grew its holdings in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Bicara Therapeutics by 73.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after purchasing an additional 1,474 shares in the last quarter. Larson Financial Group LLC lifted its position in shares of Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its stake in shares of Bicara Therapeutics by 119.6% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,109 shares of the company’s stock worth $75,000 after purchasing an additional 4,417 shares in the last quarter.

Bicara Therapeutics Price Performance

Shares of NASDAQ:BCAX opened at $18.41 on Thursday. Bicara Therapeutics Inc. has a 12 month low of $7.80 and a 12 month high of $20.25. The firm has a market capitalization of $1.01 billion, a P/E ratio of -8.22 and a beta of -0.78. The company’s fifty day moving average price is $16.93 and its 200 day moving average price is $16.21.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BCAX. Citizens Jmp assumed coverage on Bicara Therapeutics in a report on Thursday, January 29th. They issued a “market perform” rating and a $31.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a report on Tuesday, January 13th. Citigroup assumed coverage on Bicara Therapeutics in a research report on Thursday, January 29th. They set an “outperform” rating on the stock. Finally, HC Wainwright restated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Bicara Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.25.

Insider Transactions at Bicara Therapeutics

In related news, CEO Claire Mazumdar sold 36,766 shares of the company’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $19.17, for a total value of $704,804.22. Following the completion of the sale, the chief executive officer directly owned 339,392 shares of the company’s stock, valued at $6,506,144.64. This represents a 9.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Raben sold 16,300 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $18.52, for a total value of $301,876.00. Following the transaction, the insider owned 55,286 shares in the company, valued at $1,023,896.72. This represents a 22.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 113,769 shares of company stock worth $2,133,453. 15.50% of the stock is owned by company insiders.

Bicara Therapeutics Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.